From: Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases
Variable | Number of patients | % Total |
---|---|---|
Sex | ||
Male | 39 | 61.9 |
Female | 24 | 38.1 |
Year of diagnosis of BM | ||
 < 2011 | 52 | 82.5 |
 ≥ 2011 | 11 | 17.5 |
Number of BM before WBRT | ||
1–4 | 18 | 30.5 |
5–10 | 32 | 54.2 |
 > 10 | 9 | 15.3 |
Unspecified | 4 | – |
CNS progression prior to WBRT | ||
Yes | 33 | 58.9 |
No | 23 | 41.1 |
Unknown | 7 | – |
Extracranial metastases | ||
No | 20 | 31.7 |
Yes | 43 | 68.3 |
KPS | ||
 ≤ 80 | 36 | 57.1 |
 > 80 | 27 | 42.9 |
ECOG performance status | ||
0 | 14 | 22.2 |
1 | 33 | 52.4 |
2–3 | 16 | 25.4 |
Temozolomide | ||
No | 30 | 47.6 |
Yes | 33 | 52.4 |
Interleukin-2 | ||
No | 53 | 84.1 |
Yes | 10 | 15.9 |
Interferon | ||
No | 44 | 69.8 |
Yes | 19 | 30.2 |
BRAF inhibitor | ||
No | 55 | 87.3 |
Yes | 8 | 12.7 |
MEK inhibitor | ||
No | 60 | 96.8 |
Yes | 2 | 3.2 |
Missing | 1 | – |
Concurrent ipilimumab/nivolumab | ||
No | 61 | 96.8 |
Yes | 2 | 3.2 |
Post-WBRT radionecrosis | ||
No | 53 | 84.1 |
Yes | 10 | 15.9 |
Post-WBRT intralesional hemorrhage | ||
No | 43 | 68.3 |
Yes | 20 | 31.7 |
Post-WBRT memory deficits | ||
No | 51 | 81.0 |
Yes | 12 | 19.0 |
Dose of WBRT (Gy) | ||
Mean | 32.16 | – |
Median | 30 | – |
SD | 3.59 | – |
Number of WBRT fractions | ||
Mean | 11.71 | – |
Median | 10 | – |
SD | 2.81 | – |
LDH (before WBRT) | ||
Mean | 225 | – |
Median | 179 | – |
SD | 141 | – |
Age at WBRT (years) | ||
Mean | 54.21 | – |
Median | 55.45 | – |
SD | 12.18 | – |